PRO-CEFUROXIME - 500 TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
23-09-2019
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CEFUROXIME (CEFUROXIME AXETIL)
Beschikbaar vanaf:
PRO DOC LIMITEE
ATC-code:
J01DC02
INN (Algemene Internationale Benaming):
CEFUROXIME
Dosering:
500MG
farmaceutische vorm:
TABLET
Samenstelling:
CEFUROXIME (CEFUROXIME AXETIL) 500MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100
Prescription-type:
Prescription
Therapeutisch gebied:
SECOND GENERATION CEPHALOSPORINS
Product samenvatting:
Active ingredient group (AIG) number: 0122448002; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2021-05-31
Productkenmerken
Page 1 of 27
PRODUCT MONOGRAPH
PR
PRO-CEFUROXIME - 500
CEFUROXIME AXETIL TABLETS, USP
500 MG CEFUROXIME / TABLET
ANTIBIOTIC
PRO DOC LTÉE
DATE OF REVISION:
2925, boul. Industriel
September 23, 2019
Laval, Quebec
H7L 3W9
CONTROL NO.: 229806
Page 2 of 27
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
......................................................................................................
6
DRUG INTERACTIONS
.......................................................................................................
7
DOSAGE AND ADMINISTRATION
......................................................................................
8
OVERDOSAGE
....................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
9
STORAGE AND
STABILITY.................................................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 9
PART II: SCIENTIFIC INFORMATION
....................................................................................10
PHARMACEUTICAL INFORMATION
..................................................................................10
CLINICAL TRIALS
...............................................................................................................11
DETAILED PHARMACOLOGY
....
Lees het volledige document
